GLPG - Galapagos NV Stock Trading

Galapagos NV(NASDAQ: GLPG) stock trading, description, contact, officers and directors.

About Galapagos NV

Galapagos is a midsized biotechnology company, with therapeutic programs based on proprietary disease modifying drug targets, and a focus on inflammation, orphan disease, and anti infectives. Galapagos approach is to develop drugs that stop or reverse a disease state using novel targets that are identified through a patent protected target discovery platform. Galapagos also provides access to its target and drug discovery platform through its services division, BioFocus and Argenta, which offers a full suite of target to drug discovery products and services to pharmaceutical and biotech companies.

Stock Information

Galapagos NV Company Name:

GLPG Stock Symbol:

NASDAQ Market:

Galapagos NV Website:

GLPG - Galapagos NV Stock Trading

GLPG GLPG Quote GLPG Short GLPG News GLPG Articles GLPG Message Board

Get GLPG Alerts

News, Short Squeeze, Breakout and More Instantly...

GLPG - Extension of lock-up period in Gilead-Galapagos collaboration agreement

Mechelen, Belgium; 08 April 2021; 22.01 CET; Galapagos (Euronext & Nasdaq; GLPG) announced today that Gilead and Galapagos signed an amendment to the share subscription agreement closed in 2019, extending the full lock-up of Gilead’s current shareholding in Galapagos to 2...
GLPG - Publication of the annual report and invitation to the ordinary shareholders' meeting

Mechelen, Belgium; 25 March 2021; 21.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) published its annual report for the financial year 2020. The annual report for the financial year 2020, including a review of figures and performance, is availa...
GLPG - Galapagos appoints Bart Filius as President and Chief Operating Officer

Mechelen, Belgium; 24 March 2021; 21.01 CET; Galapagos (Euronext & Nasdag; GLPG) announced today that its Supervisory Board has promoted Bart Filius to President and Chief Operating Officer (COO). Going forward, CEO Onno van de Stolpe will maintain oversight of the research and develo...